Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilocarpine 1% in Pseudophakia Individuals With Presbyopia
NCT05578001Phase 3Unknown
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pilocarpine in presbyopia. Primary endpoint: Best Corrected Near Visual Acuity at 20 months. Status: unknown.
02
Drugs
pilocarpine
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT05578001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05578001.